Immunic Therapeutics
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.
Top Regions
Top Stages
1 past transactions
Vital Therapies
Acquisition in 2019
Vital Therapies, Inc. is a biotherapeutic company established in 2003 and headquartered in San Diego, California, that specializes in developing cell-based therapies aimed at treating acute liver failure. The company's primary product candidate, the ELAD System, is a bio-artificial liver therapy designed to operate extracorporeally, enabling the patient's liver to regenerate or stabilize until a transplant can be performed. The ELAD system utilizes human liver-derived C3A cells in a multi-component setup that includes hollow fiber cartridges and a bedside unit. Clinical studies of ELAD have indicated potential benefits in improving survival rates for patients with acute liver failure. The therapy has received orphan designation in both the United States and Europe for this indication. Prior to its ongoing Phase III clinical trial program, over 150 subjects participated in earlier clinical trials and compassionate use programs, suggesting a favorable therapeutic profile. Currently, Vital Therapies is initiating three Phase III clinical trials to further evaluate ELAD in different acute liver failure conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.